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Abstract We aimed to analyse the impact of breast
cancer (BC) subtypes on the clinical course of disease with
special emphasis on the occurrence of brain metastases
(BM) and outcome in an elderly BC population. A total
number of 706 patients C65 years receiving treatment for
BC from 2007 to 2011 were identified from a BC database.
62 patients diagnosed with DCIS and 73 patients with
incomplete datasets were excluded, leaving 571 patients for
this analysis. Patient characteristics, biological tumour
subtypes, and clinical outcome including overall survival
(OS) were obtained by retrospective chart review. 380/571
(66, 5 %) patients aged 65–74 years were grouped among
the young-old, 182/571 (31.9 %) patients aged 75–84 years
among the old–old, and 29/571 (5.1 %) patients aged
C85 years among the oldest-old. 392/571 (68.8 %) patients
presented with luminal BC, 119/571 (20.8 %) with HER2-
positive, and 59/571 (10.3 %) with triple-negative BC
(TNBC). At 38 months median follow-up, 115/571
(20.1 %) patients presented with distant recurrence. A
higher recurrence rate was observed in the HER2-positive
subtype (43/119 (36.1 %)), as compared to TNBC (15/59
(25.4 %)) and luminal BC (57/392 (14.5 %); p\ 0.001).
BM were detected at a significantly higher rate in HER2-
positive BC patients (9/119 (7.6 %)), as compared to
TNBC (2/59 (3.4 %)) and luminal BC patients (6/392
(1.5 %); p = 0.003). Diagnosis of metastatic disease (HR
7.7; 95 % CI 5.2–11.4; p\ 0.001) as well as development
of BM (HR 3.5; 95 % CI 1.9–6.4; p\ 0.001) had a sig-
nificantly negative impact on OS in a time-dependent
covariate cox regression model. In contrast to younger BC
patients, outcome in this large cohort of elderly patients
suggests that HER2-positive disease—not TNBC—fea-
tured the most aggressive clinical course with the highest
rates of metastatic spread and BM. In-depth analysis
regarding a potentially distinct biology of TNBC in elderly
is therefore warranted.
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Introduction
Breast cancer (BC) in elderly women is a major challenge
for modern health care systems; today, approximately
40 % of all new BC cases in developed countries are
diagnosed in women 65 years of age and older [1]. Elderly
patients are less fit to undergo standard treatment and
under-representation in clinical trials results in a lack of
evidence-based treatment recommendations [2, 3].
In addition to standard parameters such as clinical stage
and tumour biology, several age-specific aspects have to be
considered in the process of decision making in elderly
patients. Patients beyond the age of 70 have a median
number of three comorbidities [4], decreased renal [5], and
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bone marrow function [6], and physiological changes
associated with age such as increase of body fat, reduction
of body water, reduced albumin levels, and reduced bowel
motility. These factors result in altered pharmacokinetics
of antineoplastic drugs and may further increase treatment-
related toxicity [7, 8]. In addition, the number of comor-
bidities correlates with number of drugs taken daily;
indeed, a patient of 70–80 years of age receives eight to
nine tablets per day [9], thereby increasing the risk for
relevant drug–drug interactions.
BC in elderly women is postulated to have a less
aggressive biology as indicated by a higher rate of hor-
mone-receptor-positive tumours, lower grading and lower
proliferation rate as compared to younger patients [10]. On
the other hand, tumour stage at primary diagnosis is
commonly more advanced [11] due to lack of participation
in screening programmes; furthermore, even in elderly
women, a relevant number of patients will present with
tumours of aggressive biology with HER2-positive or tri-
ple-negative phenotype [12].
In HER2-positive BC, a higher rate of brain metas-
tases (BM) and shorter BM-free survival (BMFS) was
observed as compared to luminal disease [13, 14]; sim-
ilar results were reported in triple-negative BC (TNBC)
patients as well [15]. Of note, despite a recent surge of
interest in BC in elderly, limited data are available with
regard to specific BC subtypes. Therefore, we aimed to
investigate the impact of subtypes on the clinical course
of disease in an elderly BC population with a special
emphasis on BM.
Patients and methods
Elderly patients as defined by age C65 years at first BC
diagnosis receiving treatment at the Medical University of
Vienna between 2007 and 2011 were identified from a BC
database. Information relating to patient demographics,
case history, and survival were collected by retrospective
chart review. This study was conducted in accordance with
the ethical regulations of the Medical University of Vienna
and the approval by the local ethics committee was
obtained.
All patients were managed by a dedicated team of BC
specialists at an academic breast centre; treatment deci-
sions were taken in an interdisciplinary tumour conference.
Treatment was performed according to best clinical evi-
dence and according to current standard of care. No routine
brain imaging as screening for central-nervous system
(CNS) involvement was performed. Brain imaging with
MRI was only performed when clinically indicated due to
neurological symptoms.
Hormone receptor and HER2-status
Oestrogen-receptor (ER) and progesterone-receptor (PR)
status were assessed by immunohistochemistry (ERa anti-
body, clone 1D5, Dako A/S, Glostrup, Denmark; and PgR
antibody, DakoA/S, Glostrup, Denmark); hormone-receptor
expression was estimated as the percentage of positively
stained tumour cells. Results were given as 1?, 2?, and 3?
positive or negative staining, with a cut-off value of\10 %
positive tumour cells [16]. HER2-status was assessed by
immunohistochemistry (Herceptest; Dako A/S, Glostrup,
Denmark) and dual colour fluorescent in situ hybridization
(FISH; PathVision Her2 DNA probe kit, Vysis Inc.,
Downers Grove, IL, USA). Tumours were classified as
HER2-positive if they had a staining intensity of 3? on the
Herceptest; tumours with staining intensity of 2? were
tested by FISH for HER2 DNA amplification [17].
BC subtypes
BC subtypeswere defined as previously described according to
the results of immunohistochemical analysis and FISH:
Tumour specimens presenting hormone-receptor expression in
at least 10 % of cancer cells without HER2-receptor overex-
pression were defined as belonging to the luminal subtype.
HER2-positive BC was defined by strong membranous over-
expression of HER2 (IHC 3?) and/or amplification of the
HER2/neu gene. TNBCwas defined by the absence of steroid-
receptor expression as well as HER2 overexpression [18, 19].
Statistical analysis
Overall survival (OS) was defined as interval from first
diagnosis of BC until death and estimated with the Kaplan–
Meier product limit method. To test for differences
between survival curves, the log-rank test was used; to test
for impact of BM and metastases on OS, a time-dependent
covariate cox regression model was used. For correlation of
two parameters, Fisher’s exact test or v2 test was used as
appropriate. Correlation analysis was performed for sub-
types and age groups, metastatic recurrence, and BM. Two-
tailed p values\0.05 were considered to indicate statistical
significance. All statistics were calculated using statistical
package for the social sciences (SPSS) 21.0 software
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total number of 706 patients C65 years receiving treat-
ment for breast cancer from 2007 to 2011 were identified
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from a breast cancer database. 62 patients diagnosed with
DCIS and 73 patients with incomplete data were excluded,
leaving 571 patients for this analysis (Fig. 1). Median age
at primary diagnosis of BC was 73 years (range
65–94 years); three hundred eighty/571 (66.5 %) patients
aged 65–74 years were grouped among the young-old,
182/571 (31.9 %) patients aged 75–84 years among the
old–old, and 29/571 (5.1 %) patients aged C85 years
among the oldest-old, respectively.
456/571 (79.9 %) patients had steroid-receptor-positive
disease (ER-positive, both non-HER2 and HER2-positive)
and 119/571 (20.8 %) HER2 overexpression or HER2/neu
gene amplification (both ER-positive and ER-negative);
128/571 (22.4 %) patients received adjuvant chemotherapy
for early BC, while 45/571 (7.9 %) patients were diagnosed
with primary metastatic disease. Metachronous metastases
were detected in 115/571 (20.1 %) patients during their
respective course of disease; in patients with metastatic
disease, occurrence of visceral metastases either with or
without non-visceral metastases was observed in 76/115
(66.1 %) of the patients and non-visceral only disease in
39/115 (33.9 %) of the patients. Characteristics of the
overall patient population are summarized in Table 1.
The impact of BC subtypes on the clinical course
of disease
392/571 (68.8 %) patients presented with luminal BC (lu-
minal non-HER2), 119/571 (20.8 %) with HER2-positive
BC (both luminal and non-luminal disease, HER2-positive)
and 59/571 (10.3 %) with TNBC. No correlation was
observed between frequency of BC subtypes and age
groups (p[ 0.05; v2 test).
At a median follow-up of 38 months (range 0–204),
115/571 (20.1 %) patients presented with metachronous
metastatic recurrence. The highest recurrence rate was
observed in HER2-positive BC disease (43/119 (36.1 %)),
followed by TNBC (15/59 (25.4 %)) and luminal BC (57/
392 (14.5 %); p\ 0.001; v2 test). Within every subtype,
visceral metastases were more often observed than non-
visceral metastases (p[ 0.05; v2 test). The ratio of visceral
metastases was the highest in HER2-positive followed by
triple-negative and luminal metastasized disease, but this
difference did not reach statistical significance (74.4 vs.
73.3 vs. 57.9 %; p[ 0.05; v2 test).
17/571 (3 %) patients were diagnosed with BM during
their respective course of disease. BM were significantly
more often observed in HER2-positive BC patients 9/119
(7.6 %) as compared to TNBC 2/59 (3.4 %) and luminal
BC patients [6/392 (1.5 %); p = 0.003; v2 test]. Also,
significantly more patients in the group with BM had
HER2-positive disease 9/17 (52.9 %) than in patients
without BM [110/554 (19.9 %); p = 0.001; v2 test]. In
contrast, no difference was observed in patients with triple-
negative disease with or without BM [2/17 (11.8 %) vs.
58/554 (10.5 %); p[ 0.05; v2 test]. Table 2 lists patients’
characteristics according to BC subtypes.
Impact of age group on clinical course of disease
Distant metastases were most frequently observed in the
young-old group (76/115; 66.1 %) followed by the old–old
(37/115; 32.2 %) and the oldest-old group (2/115; 1.7 %).
No significant differences in the pattern of metastatic
spread were observed between the different age groups,
although a numerically higher frequency of visceral
metastases was recorded in patients of the old–old and
oldest groups. With regard to BM, 13/17 with BM (76.5 %)
were from the young-old group, while the remaining four
(23.5 %) were from the old–old group. No BM were
observed among the oldest-old patients.
Cardiovascular disease was the most frequently reported
comorbidity [382/571 (66.9 %)]; diabetes was evident in
179/571 (31.3 %) patients and renal impairment in 38/571
(6.7 %) patients at first diagnosis of BC. Patients of the
young-old group presented significantly more often with
cardiovascular comorbidities 230/382 (60.2 %) as com-
pared to patients of the old–old group 135/382 (35.3 %)
and the oldest-old group [17/382 (4.5 %); p = 0.03; v2
test], respectively. In contrast, renal impairment was sig-
nificantly more frequently observed in patients of the old–
old group 21/38 (55.3 %) compared to the young-old 14/38
(36.8 %) and the oldest-old group 3/38 (7.9 %; p = 0.002;
v2 test). No significant difference between age groups was
Fig. 1 CONSORT diagram: a total number of 706 patients
C65 years receiving treatment for breast cancer from 2007 to 2011
were identified from a breast cancer database. 62 patients diagnosed
with DCIS and 73 patients with incomplete data were excluded,
leaving 571 patients for this analysis
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Table 1 General patient’s
characteristics
Characteristics Entered patients (n = 571)
n %
Median age at BC diagnosis (years) 73
Range 65–94
Age groups
Young-old (C65–74 years) 360 66.5
Old–old (75–84 years) 182 31.9
Oldest-old (C85 years) 29 5.1
Invasive ductal carcinoma 383 67.1
Oestrogen-receptor positive 456 79.9
Progesterone-receptor positive 315 55.2
Stage IV at diagnosis 45 7.9
Proliferation rate C20 % 233 40.8
p53-positive 124 21.7
Subtypes
Luminal subtype 393 68.8
Her2-positive subtype 119 20.8
Triple-negative subtype 59 10.3
Localized disease at primary diagnosis 456 79.9
Metastatic recurrence during course of disease 115 20.1
Visceral 76 66.1
Non-visceral only 39 33.9
Occurrence of BM during course of disease 17 3
Adjuvant therapy
Chemotherapy 128 22.4
Endocrine therapy 352 61.6
Herceptin therapy 30 5.3





Characteristics Luminal HER2 Triple neg p value
n % n % n %








Young-old 246 62.6 72 60.5 42 71.2
Old–old 129 32.8 41 34.5 12 20.3 0.276
Oldest-old 18 4.6 6 5.0 5 8.5
p53-positive 54 13.7 37 31.1 33 55.9 \0.001
Grade 3 69 17.6 60 50.4 35 59.3 \0.001
Stage IV at first diagnosis 21 5.3 18 15.1 6 10.2 0.009
Metastases 57 14.5 43 36.1 15 25.4
Visceral metastases 33 57.9 32 74.4 11 73.3 0.184
Non-visceral 24 42.1 11 25.6 4 26.7
BM 6 1.5 9 7.6 2 3.4 0.003
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observed with regard to diabetes; numerically, the highest
rate was reported in the young-old group 104/179 (58.1 %)
followed by the old–old group 68/179 (38.0 %) and the
oldest-old group [7/179 (3.9 %]; p[ 0.05; v2 test).
Impact of BC subtypes and comorbidities
on survival outcome
OS in the entire patient population was 93 months (95 %
CI, 91.44–111.88) and a significant impact of age groups
on OS was observed: Median OS in the young-old group
was 110 months (95 %CI, 105.55–136.20), as compared to
74 months (95 % CI, 71.22–93.61) among old–old and
35 months (95 % CI, 29.31–55.45) among oldest-old
patients (p\ 0.001, log-rank test) (Fig. 2).
In this population of elderly patients, only a non-sig-
nificant association of BC subtypes with survival outcome
was observed: Patients with luminal disease had 95 months
median OS (95 % CI, 92.16–116.29), as compared to
88 months (95 % CI, 74.51–105.74) in patients with
HER2-positive BC and 204 months (95 % CI,
93.52–155.14) in patients with TNBC (p = 0.058, log-rank
test) (Fig. 3). Also, pattern of metastatic spread did not
correlate significantly with the OS prognosis. Patients with
visceral metastases had a median OS of 66 months (95 %
CI, 68.65–99.12) compared to 74 months (71.80–109.88)
in patients with non-visceral involvement (p[ 0.05, log-
rank test).
The presence of renal impairment was significantly
associated with shorter median OS (95 months (95 % CI,
95.85–119.36) versus 53 months (95 % CI, 52.48–81.85;
p\ 0.001, log-rank test)) (Fig. 4). All other comorbidities
did not present with a significant impact on OS prognosis.
In the Cox proportional hazard model, the triple-nega-
tive subtype had a significantly better outcome in terms of
OS even after correction for grade, nodal status, renal
impairment, and age. Table 3 summarizes the results of the
multivariate analysis of the total population as well as
triple-negative cohort.
Finally, diagnosis of metachronous metastases (HR 7.7;
95 % CI 5.2–11.4; p\ 0.001) as well as development of
BM (HR 3.5; 95 % CI 1.9–6.4; p\ 0.001) had a significant
impact on OS prognosis as entered in a time-dependent
covariate cox regression model.
Discussion
Different BC subtypes—luminal A and B, normal- and
basal-like as well as HER2-positive—have been defined on
the basis of divergent gene expression patterns. It was
shown that these subtypes have a significant impact on
clinical prognosis. In daily clinical practice, breast cancer
subtypes are usually classified as luminal, triple-negative,
and HER2-positive as defined by immunohistochemistry
and analysis of HER2/neu gene amplification.
Fig. 2 Kaplan–Meier curves in the Vienna retrospective cohort of
elderly breast cancer patients: overall survival according to age.
p values are according to the log-rank test
Fig. 3 Kaplan–Meier curves in the Vienna retrospective cohort of
elderly breast cancer patients: overall survival according to subtype.
p values are according to the log-rank test
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Henceforth, little is known about the impact of these
subtypes on prognosis specifically in elderly patients.
Therefore, we investigated survival outcomes in different
breast cancer subtypes in an elderly BC cohort of 571
patients. To our best knowledge, this is the first single-
centre cohort of this size focusing on elderly BC patients
and the specific role of disease subtypes.
Luminal breast cancer is associated with a more
favourable outcome as compared to basal-like and HER2-
enriched subtypes across all age groups [20–22]. Still, BC
survival rates are comparatively lower for women
\40 years of age than for older women across all histo-
logical subtypes and stages [23]. Many studies have con-
firmed the increased proportion of ER/PR-negativity,
HER2-overexpression, and high-grade tumours in young
women with breast cancer [24, 25]. Therefore, a higher rate
of aggressive tumour subtypes may account for the worse
outcome in patients of young age.
In contrast to younger patients, the most frequently
observed subtype in this large cohort of elderly patients
was by far the luminal subtype followed by HER2-positive
and triple-negative disease. These data are well in line with
other studies showing that the incidence of luminal BC is
increasing with age [26, 27]. Still, unfavourable tumour
phenotypes such as HER2-positive and TNBC are observed
in patients C70 years of age as well [12], necessitating
specific age-adapted treatment approaches. In this study,
we analysed for factors significantly associated with sur-
vival outcome in an elderly BC cohort with a special
emphasis on comorbidities and BM in order to improve
clinical risk assessment.
OS was 93 months in the entire population and 20.1 %
experienced disease relapse at a median follow-up of
38 months. Data from a randomized study of standard
adjuvant chemotherapy or capecitabine in elderly breast
cancer patients reported comparable recurrence rates at
3-year follow-up [28], thereby strengthening the validity of
our data.
Of note, the highest recurrence rate in this study was
observed in the HER2-positive group, indicating that
despite the availability of anti-HER2 therapy, this subtype
remains the most aggressive phenotype in elderly BC
patients. In line with that assumption, HER2-positive BC
patients had the numerically shortest OS (88 months) and
highest incidence of BM as well (7.6 %), thus indicating
that novel treatment strategies must be sought in this high-
risk population.
Indeed, BM are a devastating complication of breast
cancer; overall, only 17 patients (3 %) of this elderly
population were diagnosed with BM during their respective
course of disease, thereby suggesting that BM are less
commonly observed in elderly patients. As outlined above,
the rate of HER2-positivity was significantly higher in
patients diagnosed with BM as compared to elderly
patients without BM (52.9 vs. 19.9 %; p = 0.001); of note,
there was no difference in the rate of TNBC in patients
with or without BM (11.8 vs. 10.3 %; p[ 0.05). In addi-
tion, BM were significantly more often observed in the
HER2-positive group as compared to other subtypes
(7.6 % in patients with HER2-positive tumours vs. 3.4 %
Fig. 4 Kaplan–Meier curves in the Vienna retrospective cohort of
elderly breast cancer patients: overall survival according to renal
impairment. p value according to the log-rank test




p Hazard ratio 95 % CI p Hazard ratio 95 % CI
Grade 0.010 1.536 1.107–2.130 0.048 3.179 1.012–9.983
Nodal status \0.001 1.201 1.085–1.329 0.022 1.394 1.048–1.855
Renal impairment 0.023 1.751 1.081–2.837 0.021 18.589 1.550-222.977
Adjuvant chemotherapy 0.516 1.153 0.75–1.775 0.949 1.04 0.31–3.493
Age group \0.001 2.446 1.798–3.326 0.001 5.634 2.096–15.145
TNBC 0.020 1.941 1.112–3.387 – – –
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in TNBC and 1.5 % in luminal breast cancer;
p = 0.003).Therefore, despite the well-known high inci-
dence of BM in younger TNBC patients [29], elderly
patients with TNBC apparently were not at increased risk
for developing BM and these data suggest that develop-
ment of BM in elderly may be exclusively linked to HER2-
positivity.
Of note, Ko¨nigsberg et al. [30] also reported a—albeit
non-significantly—lower rate of BM in an elderly as
compared to a younger TNBC population (9.8 vs. 5.5 %;
n.s.). In line with those data, other publications suggested
better outcomes in elderly TNBC patients in general [31–
33], hinting at a distinct biology of triple-negative disease
in older patients. Pointing to the same direction, TNBC was
associated with numerically longest OS in our study.
To little surprise, age at primary diagnosis was shown to
have the greatest influence on OS, which can be attributed to
alternative causes of death with increasing age [34]. In an
analysis of four large trials of women with BC receiving
adjuvant chemotherapy, OSwas shorter as age increased and
older patients were more likely to die of non-breast cancer-
related causes [35], indicating the importance of comor-
bidities. In our cohort, cardiovascular disease was the most
frequently observed comorbidity and was recorded in 382
(66.9 %) of patients; still, no significant association with
survival outcome was observed. Of note, in patients with
cardiovascular disease, HER2-positivity had no significant
influence on survival indicating that the dismal prognosis of
this subtype in our study is rather due to underlying
aggressive tumour biology of HER2-positive disease than a
result of undertreatment with anti-HER2 therapy in patients
with pre-existing cardiac conditions (data not shown). Renal
impairment, in contrast, had a significant influence on OS
and occurred most frequently in patients between 75 and
84 years. In a population-based sample of 1800 post-
menopausal patients renal failure among others was also
shown to be significant in predicting early mortality and its
prevalence significantly increased with age [36]. Taken
together, these data suggest that renal impairment is a major
factor that needs to be taken into account when assessing
treatment strategies for elderly BC patients.
In the multivariate analysis of OS, grading, nodal status,
renal impairment, age as well as the triple-negative subtype
retained statistical significance. To correct for other factors
influencing the relatively good prognosis of TNBC in this
cohort of elderly patients, we performed a multivariate
analysis also within this subtype. All factors significantly
associated with OS on univariate analysis remained sig-
nificant also within the Cox regression model with the
exemption of adjuvant chemotherapy; this indicates that
the decision for systemic therapy in elderly TNBC patients
has to be carefully considered as only a limited number of
elderly women with TNBC may derive any benefit from
adjuvant treatment. Due to the retrospective design of this
analysis, however, prospective studies are required in order
to draw firm conclusions.
Although this is relatively large study, three major limi-
tations must be mentioned. First, this is a monocentric
analysis; second, the retrospective design; finally, the lack of
any comprehensive geriatric assessment in these patients.
Geriatric assessments should be considered an integral part
of cancer care in elderly patients as it may help in defining
optimal age- and risk-adapted therapy [37]. Girre et al. [38]
reported that 39 % of patients had their treatment plan
changed after geriatric assessment; in another study, some
patients with breast cancer underwent surgery for which they
were originally considered unfit [39]. Implementation of
comprehensive geriatric assessment (CGA) evidently
improves compliance, treatment tolerability, quality of life
(QoL), and survival in an elderly population [40].
In summary, to our best knowledge, this is the first
analysis of breast cancer subtypes and their prognostic
impact on clinical course and BM incidence specifically in
elderly breast cancer patients. Despite the weaknesses of a
monocentric retrospective design, we were able to establish
a clear correlation of HER2-status, recurrence rate, and BM
incidence in a large population of 571 elderly breast cancer
patients. This suggests that similar to younger patients,
elderly HER2-positive patients should be considered at
high risk for developing cerebral as well as non-cerebral
metastases, while the risk may be lower in TNBC. Further
research should therefore focus on a hypothetically distinct
biology of TNBC in an elderly BC population as well as on
the improvement of treatment strategies in HER2-positive
disease in elderly. Whether the adverse prognosis of
HER2-positive disease in elderly patients can be overcome
by novel (and potentially less toxic) treatment approaches
such as T-DM1 awaits further clarification.
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